Literature DB >> 22659419

Beta-glucosidase 1 (GBA1) is a second bile acid β-glucosidase in addition to β-glucosidase 2 (GBA2). Study in β-glucosidase deficient mice and humans.

Klaus Harzer1, Yotam Blech-Hermoni, Ehud Goldin, Ursula Felderhoff-Mueser, Claudia Igney, Ellen Sidransky, Yildiz Yildiz.   

Abstract

Beta-glucosidase 1 (GBA1; lysosomal glucocerebrosidase) and β-glucosidase 2 (GBA2, non-lysosomal glucocerebrosidase) both have glucosylceramide as a main natural substrate. The enzyme-deficient conditions with glucosylceramide accumulation are Gaucher disease (GBA-/- in humans), modelled by the Gba-/- mouse, and the syndrome with male infertility in the Gba2-/- mouse, respectively. Before the leading role of glucosylceramide was recognised for both deficient conditions, bile acid-3-O-β-glucoside (BG), another natural substrate, was viewed as the main substrate of GBA2. Given that GBA2 hydrolyses both BG and glucosylceramide, it was asked whether vice versa GBA1 hydrolyses both glucosylceramide and BG. Here we show that GBA1 also hydrolyses BG. We compared the residual BG hydrolysing activities in the GBA1-/-, Gba1-/- conditions (where GBA2 is the almost only active β-glucosidase) and those in the Gba2-/- condition (GBA1 active), with wild-type activities, but we used also the GBA1 inhibitor isofagomine. GBA1 and GBA2 activities had characteristic differences between the studied fibroblast, liver and brain samples. Independently, the hydrolysis of BG by pure recombinant GBA1 was shown. The fact that both GBA1 and GBA2 are glucocerebrosidases as well as bile acid β-glucosidases raises the question, why lysosomal accumulation of glucosylceramide in GBA1 deficiency, and extra-lysosomal accumulation in GBA2 deficiency, are not associated with an accumulation of BG in either condition.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659419      PMCID: PMC3529407          DOI: 10.1016/j.bbrc.2012.05.117

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  The cytosolic β-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation.

Authors:  Nick Dekker; Tineke Voorn-Brouwer; Marri Verhoek; Tom Wennekes; Ravi S Narayan; Dave Speijer; Carla E M Hollak; Hermen S Overkleeft; Rolf G Boot; Johannes M F G Aerts
Journal:  Blood Cells Mol Dis       Date:  2010-08-21       Impact factor: 3.039

2.  The enzymatic hydrolysis of 6-acylamino-4-methylumbelliferyl-beta-D-glucosides: identification of a novel human acid beta-glucosidase.

Authors:  M Mikhaylova; G Wiederschain; V Mikhaylov; J M Aerts
Journal:  Biochim Biophys Acta       Date:  1996-10-07

3.  Purification and characterization of a cytosolic broad specificity beta-glucosidase from human liver.

Authors:  L B Daniels; P J Coyle; Y B Chiao; R H Glew; R S Labow
Journal:  J Biol Chem       Date:  1981-12-25       Impact factor: 5.157

4.  Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation.

Authors:  E Orvisky; E Sidransky; C E McKinney; M E Lamarca; R Samimi; D Krasnewich; B M Martin; E I Ginns
Journal:  Pediatr Res       Date:  2000-08       Impact factor: 3.756

5.  Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility.

Authors:  Yildiz Yildiz; Heidrun Matern; Bonne Thompson; Jeremy C Allegood; Rebekkah L Warren; Denise M O Ramirez; Robert E Hammer; F Kent Hamra; Siegfried Matern; David W Russell
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

6.  Purification and characterization of a microsomal bile acid beta-glucosidase from human liver.

Authors:  H Matern; H Heinemann; G Legler; S Matern
Journal:  J Biol Chem       Date:  1997-04-25       Impact factor: 5.157

7.  Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease.

Authors:  S van Weely; M Brandsma; A Strijland; J M Tager; J M Aerts
Journal:  Biochim Biophys Acta       Date:  1993-03-24

8.  Beta-glucosidase activity towards a bile acid glucoside in human liver.

Authors:  H Matern; R Gartzen; S Matern
Journal:  FEBS Lett       Date:  1992-12-14       Impact factor: 4.124

9.  Intrauterine onset of acute neuropathic type 2 Gaucher disease: identification of a novel insertion sequence.

Authors:  Ursula Felderhoff-Mueser; Johannes Uhl; Roland Penzel; Frank Van Landeghem; Martin Vogel; Michael Obladen; Jürgen Kopitz
Journal:  Am J Med Genet A       Date:  2004-07-15       Impact factor: 2.802

10.  Evaluation of isofagomine and its derivatives as potent glycosidase inhibitors.

Authors:  W Dong; T Jespersen; M Bols; T Skrydstrup; M R Sierks
Journal:  Biochemistry       Date:  1996-02-27       Impact factor: 3.162

View more
  4 in total

1.  Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease.

Authors:  Pramod K Mistry; Jun Liu; Li Sun; Wei-Lien Chuang; Tony Yuen; Ruhua Yang; Ping Lu; Kate Zhang; Jianhua Li; Joan Keutzer; Agnes Stachnik; Albert Mennone; James L Boyer; Dhanpat Jain; Roscoe O Brady; Maria I New; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

2.  Expression of a secretory α-glucosidase II from Apis cerana indica in Pichia pastoris and its characterization.

Authors:  Jirattikarn Kaewmuangmoon; Manlika Kilaso; Ubolsree Leartsakulpanich; Kiyoshi Kimura; Atsuo Kimura; Chanpen Chanchao
Journal:  BMC Biotechnol       Date:  2013-02-18       Impact factor: 2.563

3.  Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease.

Authors:  Yildiz Yildiz; Per Hoffmann; Stefan Vom Dahl; Bernadette Breiden; Roger Sandhoff; Claus Niederau; Mia Horwitz; Stefan Karlsson; Mirella Filocamo; Deborah Elstein; Michael Beck; Konrad Sandhoff; Eugen Mengel; Maria C Gonzalez; Markus M Nöthen; Ellen Sidransky; Ari Zimran; Manuel Mattheisen
Journal:  Orphanet J Rare Dis       Date:  2013-09-26       Impact factor: 4.123

4.  Transcriptomic characterization of tissues from patients and subsequent pathway analyses reveal biological pathways that are implicated in spastic ataxia.

Authors:  Andrea C Kakouri; Christina Votsi; Anastasis Oulas; Paschalis Nicolaou; Massimo Aureli; Giulia Lunghi; Maura Samarani; Giacomo M Compagnoni; Sabrina Salani; Alessio Di Fonzo; Thalis Christophides; George A Tanteles; Eleni Zamba-Papanicolaou; Marios Pantzaris; George M Spyrou; Kyproula Christodoulou
Journal:  Cell Biosci       Date:  2022-03-11       Impact factor: 7.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.